Ipamorelin: what the evidence actually shows

Ipamorelin is a selective growth hormone secretagogue that acts at the ghrelin receptor.

Also known as ipamorelin acetate.

Evidence and regulatory status

In registered human trials. Not approved for this use.

Not approved by the FDA for any indication. Prohibited in sport as a growth hormone secretagogue.

Half-life

A half-life figure for Ipamorelin has not been verified against a primary source for this page, so none is stated. The sources below are where a figure would come from.

What published trials used

No published human dosing trial exists for Ipamorelin.

Reported for reference only. What a trial administered under supervision is not a recommendation, and Gireta does not make one.

How much research exists

PubMed records
54
Tagged human
28
Clinical trials
2

A PubMed search for Ipamorelin returns 54 records, of which 28 are tagged as human research and 2 are typed as a clinical trial.

Counted on . Counts drift, so the exact query is linked rather than described, and you can re-run it.

Common questions

Has ipamorelin been tested in humans?
It reached human trials for postoperative ileus rather than for body composition, and it was not approved. The published human evidence is small: two records typed as clinical trials.
Is ipamorelin FDA approved?
No. Ipamorelin has never been approved by the FDA for any indication.
What is the half-life of ipamorelin?
No published human pharmacokinetic study has been verified against a primary source for this page, so no half-life figure is stated here.

Sources

  1. Ipamorelin ileus trial · International Journal of Colorectal Disease, via PubMed, 2014

Related compounds

Growth hormone secretagogues

Prompt the pituitary to release growth hormone rather than supplying growth hormone directly.

  • Tesamorelin Tesamorelin is a synthetic growth hormone-releasing factor analogue approved to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy.
  • Ibutamoren Ibutamoren is an orally active ghrelin receptor agonist that raises growth hormone and IGF-1 levels.
  • CJC-1295 CJC-1295 is a long-acting analogue of growth hormone-releasing hormone, modified to bind albumin and extend its duration of action.

Planning a schedule?

Gireta turns a compound and a cadence into a twelve-week timeline with the reconstitution maths worked out and a monthly cost.

Plan a Ipamorelin schedule

Last reviewed .